Dupont Capital Management’s Travere Therapeutics TVTX Stock Holding History

Dupont Capital Management’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-12,891	Closed	-$312K	–	1678
2022 Q2	$312K	Hold	12,891	–	–	0.01%	849
2022 Q1	$332K	Sell	12,891 -1,141	-8%	-$30.3K	0.01%	896
2021 Q4	$436K	Sell	14,032 -5,595	-29%	-$158K	0.02%	858
2021 Q3	$476K	Sell	19,627 -2,774	-12%	-$51K	0.02%	914
2021 Q2	$327K	Hold	22,401	–	–	0.01%	1169
2021 Q1	$559K	Sell	22,401 -4,594	-17%	-$127K	0.01%	866
2020 Q4	$736K	Sell	26,995 -2,015	-7%	-$47K	0.02%	686
2020 Q3	$536K	Buy	29,010 +9,496	+49%	+$185K	0.01%	718
2020 Q2	$398K	Sell	19,514 -1,743	-8%	-$27.8K	0.01%	871
2020 Q1	$310K	Buy	+21,257	New	+$320K	0.01%	847
2016 Q4	–	Sell	-38,018	Closed	-$851K	–	870
2016 Q3	$851K	Buy	+38,018	New	+$724K	0.02%	490

Other funds holding TVTX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Dupont Capital Management's TVTX Position: Q3 2022 in Review

Dupont Capital Management sold out of Travere Therapeutics (TVTX) in Q3 2022, closing a stake of 12,891 shares — an estimated $312K sold.

Dupont Capital Management first reported a position in TVTX in Q3 2016 and held it in 11 quarters. The position peaked at $851K in Q3 2016. 171 funds tracked by Wall St. Rank hold TVTX as of Q3 2022.

Dupont Capital Management reported no remaining Travere Therapeutics position as of Q3 2022 after selling out during the quarter.
Dupont Capital Management sold 12,891 Travere Therapeutics shares in Q3 2022, an estimated $312K.
Dupont Capital Management first reported a position in Travere Therapeutics in Q3 2016 and held it in 11 quarters.
Dupont Capital Management's Travere Therapeutics position peaked at $851K in Q3 2016.
171 funds tracked by Wall St. Rank held Travere Therapeutics as of Q3 2022.

Based on Dupont Capital Management's 13F filing for Q3 2022, filed 31 Oct 2022.